Of these c-MET-negative lesions, 9/18 (50.0%) were lung metastases with a SAD > 0.5 cm, 5/18 (27.8%) were liver metastases (in a patient with disseminated liver metastases), 2/18 (11.1%) were lymph node metastases, 1/18 (5.6%) was a subcutaneous soft tissue metastasis, and 1/18 (5.6%) was a bone metastasis. This evidence concerns the gene MET and bone metastasis.